CytomX Therapeutics (NASDAQ:CTMX) CEO Sean Mccarthy Sells 118,969 Shares of Stock

CytomX Therapeutics, Inc. (NASDAQ:CTMX) CEO Sean Mccarthy sold 118,969 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $6.42, for a total transaction of $763,780.98. Following the completion of the transaction, the chief executive officer owned 1,078,922 shares in the company, valued at $6,926,679.24. This trade represents a 9.93% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

CytomX Therapeutics Stock Up 8.3%

CTMX opened at $4.77 on Friday. CytomX Therapeutics, Inc. has a twelve month low of $0.40 and a twelve month high of $8.21. The company has a fifty day moving average of $5.28 and a 200-day moving average of $4.10. The stock has a market cap of $810.96 million, a PE ratio of -119.13 and a beta of 2.44.

CytomX Therapeutics (NASDAQ:CTMX) last released its earnings results on Monday, March 16th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.14). The firm had revenue of $0.66 million during the quarter, compared to analyst estimates of $7.33 million. CytomX Therapeutics had a negative net margin of 22.79% and a negative return on equity of 19.77%. Sell-side analysts anticipate that CytomX Therapeutics, Inc. will post -0.05 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Barclays upped their target price on CytomX Therapeutics from $10.00 to $16.00 and gave the company an “overweight” rating in a research report on Thursday. JPMorgan Chase & Co. upgraded CytomX Therapeutics from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $7.00 to $12.00 in a report on Monday. Guggenheim boosted their price target on CytomX Therapeutics from $10.00 to $15.00 and gave the company a “buy” rating in a research note on Wednesday. Piper Sandler increased their price target on CytomX Therapeutics from $6.50 to $10.00 and gave the stock an “overweight” rating in a report on Tuesday, January 20th. Finally, Jefferies Financial Group raised their price objective on shares of CytomX Therapeutics from $8.00 to $16.00 and gave the stock a “buy” rating in a research report on Wednesday. Nine analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $13.22.

Institutional Trading of CytomX Therapeutics

Several large investors have recently made changes to their positions in the company. Wells Fargo & Company MN increased its position in CytomX Therapeutics by 83.2% in the 4th quarter. Wells Fargo & Company MN now owns 6,605 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 3,000 shares in the last quarter. Farther Finance Advisors LLC bought a new position in CytomX Therapeutics in the third quarter worth approximately $25,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in CytomX Therapeutics in the fourth quarter valued at approximately $35,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new stake in CytomX Therapeutics in the third quarter valued at approximately $34,000. Finally, May Hill Capital LLC bought a new stake in shares of CytomX Therapeutics during the fourth quarter valued at approximately $46,000. 67.77% of the stock is currently owned by institutional investors and hedge funds.

More CytomX Therapeutics News

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Barclays raised its price target to $16 and put CTMX at “overweight,” signaling strong upside potential that likely fueled buying interest. Barclays price-target raise
• Positive Sentiment: Guggenheim increased its forecast/price target and reiterated a bullish view on the stock, another catalyst supporting the rally. Guggenheim Forecasts Strong Price Appreciation for CytomX
• Positive Sentiment: Wedbush also lifted its price target (to $11), adding to the cluster of upgrades that have altered investor sentiment. Wedbush Raises Price Target
• Positive Sentiment: Market reaction: the stock saw strong trading volume after the analyst upgrade cycle, suggesting the upgrades are driving real buying interest rather than only headline noise. Strong Trading Volume After Analyst Upgrade
• Neutral Sentiment: CytomX priced an equity offering for roughly $234 million — this bolsters the balance sheet and funding runway (positive) but is dilutive (negative), so its net effect is mixed for investors. Equity Offering Announcement
• Negative Sentiment: CytomX reported disappointing quarterly results (EPS and revenue misses), which is a near‑term negative and helps explain some intraday volatility. Shares Down on Disappointing Earnings
• Negative Sentiment: An analyst reduced the Q1 EPS forecast, increasing uncertainty around near‑term fundamentals. Q1 EPS Forecast Decreased
• Negative Sentiment: Several insiders (including the CEO, CFO and other senior execs) sold shares on March 17, which can be perceived as a signal of reduced insider conviction and may weigh on sentiment. SEC Form 4 — CEO Sale
• Negative Sentiment: Commentary cautioning that early clinical data may not yet justify elevated valuations adds a note of skepticism for momentum traders. Seeking Alpha valuation caution

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.